These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28827861)

  • 1. The prospective, 24-week assessment of cost-efficacy of and compliance to antidepressant medications in a rural setting (PACECAR) study.
    Rao TSS; Manohar JS; Raman R; Darshan MS; Tandon A; Karthik KN; Saraswathi N; Das K; Harsha GT; Kunkeri SP; Andrade C
    Indian J Psychiatry; 2017; 59(2):157-163. PubMed ID: 28827861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Hatano M; Matsuda Y; Iwata N
    Mol Psychiatry; 2023 Jan; 28(1):402-409. PubMed ID: 36253442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
    Dolder C; Nelson M; Stump A
    Drugs Aging; 2010 Aug; 27(8):625-40. PubMed ID: 20658791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
    Rao Y; Yang R; Zhao J; Cao Q
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 51(4):480-490. PubMed ID: 37202104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-minimization analysis of escitalopram, fluoxetine, and amitriptyline in the treatment of depression.
    Salian HH; Raghav MV; Rawat VS; Divakar A
    Indian J Pharmacol; 2023; 55(5):293-298. PubMed ID: 37929407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT.
    Tesfaye S; Sloan G; Petrie J; White D; Bradburn M; Young T; Rajbhandari S; Sharma S; Rayman G; Gouni R; Alam U; Julious SA; Cooper C; Loban A; Sutherland K; Glover R; Waterhouse S; Turton E; Horspool M; Gandhi R; Maguire D; Jude E; Ahmed SH; Vas P; Hariman C; McDougall C; Devers M; Tsatlidis V; Johnson M; Bouhassira D; Bennett DL; Selvarajah D
    Health Technol Assess; 2022 Oct; 26(39):1-100. PubMed ID: 36259684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
    Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
    Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug events associated with nortriptyline compared with paroxetine and alternative medications in an older adult population: a retrospective cohort study in Southern California.
    George MM; Deamer RL; Do D
    BMJ Open; 2023 Dec; 13(12):e076028. PubMed ID: 38154883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
    Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.
    Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV
    Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
    Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial.
    Gupta BM; Zargar SH; Arora M; Tandon VR
    Perspect Clin Res; 2016; 7(1):45-50. PubMed ID: 26955576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data.
    Solem CT; Shelbaya A; Wan Y; Deshpande CG; Alvir J; Pappadopulos E
    Neuropsychiatr Dis Treat; 2016; 12():2755-2764. PubMed ID: 27822048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.